BIOX: Revenue declined 18% amid restructuring, but cost actions drove Q4 EBITDA back to positive
Fiscal 2026 saw an 18% revenue decline due to litigation and business restructuring, but Q4 showed stabilization with cost reductions and a return to positive adjusted EBITDA. The company targets 40% gross margins and further SG&A reductions, while ongoing legal disputes and debt management remain…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.